Global Nanobody Drug Market Growth 2026-2032
The global Nanobody Drug market size is predicted to grow from US$ 718 million in 2025 to US$ 2851 million in 2032; it is expected to grow at a CAGR of 22.2% from 2026 to 2032.
United States market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Nanobody Drug players cover Boehringer Ingelheim, Sanofi Company(Ablynx), Merck KGaA, Jerry Corning, Shenzhen Pregene Biopharma Co, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Nanobody Drug Industry Forecast” looks at past sales and reviews total world Nanobody Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Nanobody Drug sales for 2026 through 2032. With Nanobody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nanobody Drug industry.
This Insight Report provides a comprehensive analysis of the global Nanobody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nanobody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nanobody Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nanobody Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nanobody Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Nanobody Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
United States market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Nanobody Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Nanobody Drug players cover Boehringer Ingelheim, Sanofi Company(Ablynx), Merck KGaA, Jerry Corning, Shenzhen Pregene Biopharma Co, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Nanobody Drug Industry Forecast” looks at past sales and reviews total world Nanobody Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Nanobody Drug sales for 2026 through 2032. With Nanobody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nanobody Drug industry.
This Insight Report provides a comprehensive analysis of the global Nanobody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nanobody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nanobody Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nanobody Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nanobody Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Nanobody Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monovalent Nanobodies
- Multivalent Nanobodies
- Fusion Nanobodies
- Others
- Tumor Treatment
- Immune Disease Treatment
- Inflammatory Disease Treatment
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Boehringer Ingelheim
- Sanofi Company(Ablynx)
- Merck KGaA
- Jerry Corning
- Shenzhen Pregene Biopharma Co
- Novamab
- PersonGen
- Nanjing Legend Biotechnology Co., Ltd.
- Taiwan Taisho Pharmaceutical
- Yiteng Pharmaceutical
- Beijing Shuoxing Biotechnology
- What is the 10-year outlook for the global Nanobody Drug market?
- What factors are driving Nanobody Drug market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Nanobody Drug market opportunities vary by end market size?
- How does Nanobody Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nanobody Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Nanobody Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Nanobody Drug by Country/Region, 2021, 2025 & 2032
2.2 Nanobody Drug Segment by Type
2.2.1 Monovalent Nanobodies
2.2.2 Multivalent Nanobodies
2.2.3 Fusion Nanobodies
2.2.4 Others
2.2.5 Nanobody Drug Sales by Type
2.2.5.1 Global Nanobody Drug Sales Market Share by Type (2021-2026)
2.2.5.2 Global Nanobody Drug Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Nanobody Drug Sale Price by Type (2021-2026)
2.3 Nanobody Drug Segment by Application
2.3.1 Tumor Treatment
2.3.2 Immune Disease Treatment
2.3.3 Inflammatory Disease Treatment
2.3.4 Others
2.3.5 Nanobody Drug Sales by Application
2.3.5.1 Global Nanobody Drug Sale Market Share by Application (2021-2026)
2.3.5.2 Global Nanobody Drug Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Nanobody Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Nanobody Drug Breakdown Data by Company
3.1.1 Global Nanobody Drug Annual Sales by Company (2021-2026)
3.1.2 Global Nanobody Drug Sales Market Share by Company (2021-2026)
3.2 Global Nanobody Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Nanobody Drug Revenue by Company (2021-2026)
3.2.2 Global Nanobody Drug Revenue Market Share by Company (2021-2026)
3.3 Global Nanobody Drug Sale Price by Company
3.4 Key Manufacturers Nanobody Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nanobody Drug Product Location Distribution
3.4.2 Players Nanobody Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NANOBODY DRUG BY GEOGRAPHIC REGION
4.1 World Historic Nanobody Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Nanobody Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Nanobody Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Nanobody Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Nanobody Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Nanobody Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Nanobody Drug Sales Growth
4.4 APAC Nanobody Drug Sales Growth
4.5 Europe Nanobody Drug Sales Growth
4.6 Middle East & Africa Nanobody Drug Sales Growth
5 AMERICAS
5.1 Americas Nanobody Drug Sales by Country
5.1.1 Americas Nanobody Drug Sales by Country (2021-2026)
5.1.2 Americas Nanobody Drug Revenue by Country (2021-2026)
5.2 Americas Nanobody Drug Sales by Type (2021-2026)
5.3 Americas Nanobody Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nanobody Drug Sales by Region
6.1.1 APAC Nanobody Drug Sales by Region (2021-2026)
6.1.2 APAC Nanobody Drug Revenue by Region (2021-2026)
6.2 APAC Nanobody Drug Sales by Type (2021-2026)
6.3 APAC Nanobody Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nanobody Drug by Country
7.1.1 Europe Nanobody Drug Sales by Country (2021-2026)
7.1.2 Europe Nanobody Drug Revenue by Country (2021-2026)
7.2 Europe Nanobody Drug Sales by Type (2021-2026)
7.3 Europe Nanobody Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nanobody Drug by Country
8.1.1 Middle East & Africa Nanobody Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Nanobody Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Nanobody Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Nanobody Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nanobody Drug
10.3 Manufacturing Process Analysis of Nanobody Drug
10.4 Industry Chain Structure of Nanobody Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nanobody Drug Distributors
11.3 Nanobody Drug Customer
12 WORLD FORECAST REVIEW FOR NANOBODY DRUG BY GEOGRAPHIC REGION
12.1 Global Nanobody Drug Market Size Forecast by Region
12.1.1 Global Nanobody Drug Forecast by Region (2027-2032)
12.1.2 Global Nanobody Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Nanobody Drug Forecast by Type (2027-2032)
12.7 Global Nanobody Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Nanobody Drug Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Sanofi Company(Ablynx)
13.2.1 Sanofi Company(Ablynx) Company Information
13.2.2 Sanofi Company(Ablynx) Nanobody Drug Product Portfolios and Specifications
13.2.3 Sanofi Company(Ablynx) Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Company(Ablynx) Main Business Overview
13.2.5 Sanofi Company(Ablynx) Latest Developments
13.3 Merck KGaA
13.3.1 Merck KGaA Company Information
13.3.2 Merck KGaA Nanobody Drug Product Portfolios and Specifications
13.3.3 Merck KGaA Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck KGaA Main Business Overview
13.3.5 Merck KGaA Latest Developments
13.4 Jerry Corning
13.4.1 Jerry Corning Company Information
13.4.2 Jerry Corning Nanobody Drug Product Portfolios and Specifications
13.4.3 Jerry Corning Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Jerry Corning Main Business Overview
13.4.5 Jerry Corning Latest Developments
13.5 Shenzhen Pregene Biopharma Co
13.5.1 Shenzhen Pregene Biopharma Co Company Information
13.5.2 Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolios and Specifications
13.5.3 Shenzhen Pregene Biopharma Co Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Shenzhen Pregene Biopharma Co Main Business Overview
13.5.5 Shenzhen Pregene Biopharma Co Latest Developments
13.6 Novamab
13.6.1 Novamab Company Information
13.6.2 Novamab Nanobody Drug Product Portfolios and Specifications
13.6.3 Novamab Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Novamab Main Business Overview
13.6.5 Novamab Latest Developments
13.7 PersonGen
13.7.1 PersonGen Company Information
13.7.2 PersonGen Nanobody Drug Product Portfolios and Specifications
13.7.3 PersonGen Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 PersonGen Main Business Overview
13.7.5 PersonGen Latest Developments
13.8 Nanjing Legend Biotechnology Co., Ltd.
13.8.1 Nanjing Legend Biotechnology Co., Ltd. Company Information
13.8.2 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolios and Specifications
13.8.3 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nanjing Legend Biotechnology Co., Ltd. Main Business Overview
13.8.5 Nanjing Legend Biotechnology Co., Ltd. Latest Developments
13.9 Taiwan Taisho Pharmaceutical
13.9.1 Taiwan Taisho Pharmaceutical Company Information
13.9.2 Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolios and Specifications
13.9.3 Taiwan Taisho Pharmaceutical Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Taiwan Taisho Pharmaceutical Main Business Overview
13.9.5 Taiwan Taisho Pharmaceutical Latest Developments
13.10 Yiteng Pharmaceutical
13.10.1 Yiteng Pharmaceutical Company Information
13.10.2 Yiteng Pharmaceutical Nanobody Drug Product Portfolios and Specifications
13.10.3 Yiteng Pharmaceutical Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Yiteng Pharmaceutical Main Business Overview
13.10.5 Yiteng Pharmaceutical Latest Developments
13.11 Beijing Shuoxing Biotechnology
13.11.1 Beijing Shuoxing Biotechnology Company Information
13.11.2 Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolios and Specifications
13.11.3 Beijing Shuoxing Biotechnology Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Beijing Shuoxing Biotechnology Main Business Overview
13.11.5 Beijing Shuoxing Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nanobody Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Nanobody Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Nanobody Drug by Country/Region, 2021, 2025 & 2032
2.2 Nanobody Drug Segment by Type
2.2.1 Monovalent Nanobodies
2.2.2 Multivalent Nanobodies
2.2.3 Fusion Nanobodies
2.2.4 Others
2.2.5 Nanobody Drug Sales by Type
2.2.5.1 Global Nanobody Drug Sales Market Share by Type (2021-2026)
2.2.5.2 Global Nanobody Drug Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Nanobody Drug Sale Price by Type (2021-2026)
2.3 Nanobody Drug Segment by Application
2.3.1 Tumor Treatment
2.3.2 Immune Disease Treatment
2.3.3 Inflammatory Disease Treatment
2.3.4 Others
2.3.5 Nanobody Drug Sales by Application
2.3.5.1 Global Nanobody Drug Sale Market Share by Application (2021-2026)
2.3.5.2 Global Nanobody Drug Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Nanobody Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Nanobody Drug Breakdown Data by Company
3.1.1 Global Nanobody Drug Annual Sales by Company (2021-2026)
3.1.2 Global Nanobody Drug Sales Market Share by Company (2021-2026)
3.2 Global Nanobody Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Nanobody Drug Revenue by Company (2021-2026)
3.2.2 Global Nanobody Drug Revenue Market Share by Company (2021-2026)
3.3 Global Nanobody Drug Sale Price by Company
3.4 Key Manufacturers Nanobody Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nanobody Drug Product Location Distribution
3.4.2 Players Nanobody Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NANOBODY DRUG BY GEOGRAPHIC REGION
4.1 World Historic Nanobody Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Nanobody Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Nanobody Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Nanobody Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Nanobody Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Nanobody Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Nanobody Drug Sales Growth
4.4 APAC Nanobody Drug Sales Growth
4.5 Europe Nanobody Drug Sales Growth
4.6 Middle East & Africa Nanobody Drug Sales Growth
5 AMERICAS
5.1 Americas Nanobody Drug Sales by Country
5.1.1 Americas Nanobody Drug Sales by Country (2021-2026)
5.1.2 Americas Nanobody Drug Revenue by Country (2021-2026)
5.2 Americas Nanobody Drug Sales by Type (2021-2026)
5.3 Americas Nanobody Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nanobody Drug Sales by Region
6.1.1 APAC Nanobody Drug Sales by Region (2021-2026)
6.1.2 APAC Nanobody Drug Revenue by Region (2021-2026)
6.2 APAC Nanobody Drug Sales by Type (2021-2026)
6.3 APAC Nanobody Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nanobody Drug by Country
7.1.1 Europe Nanobody Drug Sales by Country (2021-2026)
7.1.2 Europe Nanobody Drug Revenue by Country (2021-2026)
7.2 Europe Nanobody Drug Sales by Type (2021-2026)
7.3 Europe Nanobody Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nanobody Drug by Country
8.1.1 Middle East & Africa Nanobody Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Nanobody Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Nanobody Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Nanobody Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nanobody Drug
10.3 Manufacturing Process Analysis of Nanobody Drug
10.4 Industry Chain Structure of Nanobody Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nanobody Drug Distributors
11.3 Nanobody Drug Customer
12 WORLD FORECAST REVIEW FOR NANOBODY DRUG BY GEOGRAPHIC REGION
12.1 Global Nanobody Drug Market Size Forecast by Region
12.1.1 Global Nanobody Drug Forecast by Region (2027-2032)
12.1.2 Global Nanobody Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Nanobody Drug Forecast by Type (2027-2032)
12.7 Global Nanobody Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Nanobody Drug Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Sanofi Company(Ablynx)
13.2.1 Sanofi Company(Ablynx) Company Information
13.2.2 Sanofi Company(Ablynx) Nanobody Drug Product Portfolios and Specifications
13.2.3 Sanofi Company(Ablynx) Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Company(Ablynx) Main Business Overview
13.2.5 Sanofi Company(Ablynx) Latest Developments
13.3 Merck KGaA
13.3.1 Merck KGaA Company Information
13.3.2 Merck KGaA Nanobody Drug Product Portfolios and Specifications
13.3.3 Merck KGaA Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck KGaA Main Business Overview
13.3.5 Merck KGaA Latest Developments
13.4 Jerry Corning
13.4.1 Jerry Corning Company Information
13.4.2 Jerry Corning Nanobody Drug Product Portfolios and Specifications
13.4.3 Jerry Corning Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Jerry Corning Main Business Overview
13.4.5 Jerry Corning Latest Developments
13.5 Shenzhen Pregene Biopharma Co
13.5.1 Shenzhen Pregene Biopharma Co Company Information
13.5.2 Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolios and Specifications
13.5.3 Shenzhen Pregene Biopharma Co Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Shenzhen Pregene Biopharma Co Main Business Overview
13.5.5 Shenzhen Pregene Biopharma Co Latest Developments
13.6 Novamab
13.6.1 Novamab Company Information
13.6.2 Novamab Nanobody Drug Product Portfolios and Specifications
13.6.3 Novamab Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Novamab Main Business Overview
13.6.5 Novamab Latest Developments
13.7 PersonGen
13.7.1 PersonGen Company Information
13.7.2 PersonGen Nanobody Drug Product Portfolios and Specifications
13.7.3 PersonGen Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 PersonGen Main Business Overview
13.7.5 PersonGen Latest Developments
13.8 Nanjing Legend Biotechnology Co., Ltd.
13.8.1 Nanjing Legend Biotechnology Co., Ltd. Company Information
13.8.2 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolios and Specifications
13.8.3 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nanjing Legend Biotechnology Co., Ltd. Main Business Overview
13.8.5 Nanjing Legend Biotechnology Co., Ltd. Latest Developments
13.9 Taiwan Taisho Pharmaceutical
13.9.1 Taiwan Taisho Pharmaceutical Company Information
13.9.2 Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolios and Specifications
13.9.3 Taiwan Taisho Pharmaceutical Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Taiwan Taisho Pharmaceutical Main Business Overview
13.9.5 Taiwan Taisho Pharmaceutical Latest Developments
13.10 Yiteng Pharmaceutical
13.10.1 Yiteng Pharmaceutical Company Information
13.10.2 Yiteng Pharmaceutical Nanobody Drug Product Portfolios and Specifications
13.10.3 Yiteng Pharmaceutical Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Yiteng Pharmaceutical Main Business Overview
13.10.5 Yiteng Pharmaceutical Latest Developments
13.11 Beijing Shuoxing Biotechnology
13.11.1 Beijing Shuoxing Biotechnology Company Information
13.11.2 Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolios and Specifications
13.11.3 Beijing Shuoxing Biotechnology Nanobody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Beijing Shuoxing Biotechnology Main Business Overview
13.11.5 Beijing Shuoxing Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Nanobody Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Nanobody Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monovalent Nanobodies
Table 4. Major Players of Multivalent Nanobodies
Table 5. Major Players of Fusion Nanobodies
Table 6. Major Players of Others
Table 7. Global Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 8. Global Nanobody Drug Sales Market Share by Type (2021-2026)
Table 9. Global Nanobody Drug Revenue by Type (2021-2026) & ($ million)
Table 10. Global Nanobody Drug Revenue Market Share by Type (2021-2026)
Table 11. Global Nanobody Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Nanobody Drug Sale by Application (2021-2026) & (K Units)
Table 13. Global Nanobody Drug Sale Market Share by Application (2021-2026)
Table 14. Global Nanobody Drug Revenue by Application (2021-2026) & ($ million)
Table 15. Global Nanobody Drug Revenue Market Share by Application (2021-2026)
Table 16. Global Nanobody Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Nanobody Drug Sales by Company (2021-2026) & (K Units)
Table 18. Global Nanobody Drug Sales Market Share by Company (2021-2026)
Table 19. Global Nanobody Drug Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Nanobody Drug Revenue Market Share by Company (2021-2026)
Table 21. Global Nanobody Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Nanobody Drug Producing Area Distribution and Sales Area
Table 23. Players Nanobody Drug Products Offered
Table 24. Nanobody Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Nanobody Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Nanobody Drug Sales Market Share Geographic Region (2021-2026)
Table 29. Global Nanobody Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Nanobody Drug Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Nanobody Drug Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Nanobody Drug Sales Market Share by Country/Region (2021-2026)
Table 33. Global Nanobody Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Nanobody Drug Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 36. Americas Nanobody Drug Sales Market Share by Country (2021-2026)
Table 37. Americas Nanobody Drug Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 39. Americas Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 40. APAC Nanobody Drug Sales by Region (2021-2026) & (K Units)
Table 41. APAC Nanobody Drug Sales Market Share by Region (2021-2026)
Table 42. APAC Nanobody Drug Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 44. APAC Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 45. Europe Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 46. Europe Nanobody Drug Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 48. Europe Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Nanobody Drug Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Nanobody Drug
Table 54. Key Market Challenges & Risks of Nanobody Drug
Table 55. Key Industry Trends of Nanobody Drug
Table 56. Nanobody Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Nanobody Drug Distributors List
Table 59. Nanobody Drug Customer List
Table 60. Global Nanobody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Nanobody Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Nanobody Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Nanobody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Nanobody Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Nanobody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Nanobody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Nanobody Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Nanobody Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Nanobody Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Nanobody Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Boehringer Ingelheim Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Boehringer Ingelheim Nanobody Drug Product Portfolios and Specifications
Table 76. Boehringer Ingelheim Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Boehringer Ingelheim Main Business
Table 78. Boehringer Ingelheim Latest Developments
Table 79. Sanofi Company(Ablynx) Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Sanofi Company(Ablynx) Nanobody Drug Product Portfolios and Specifications
Table 81. Sanofi Company(Ablynx) Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Sanofi Company(Ablynx) Main Business
Table 83. Sanofi Company(Ablynx) Latest Developments
Table 84. Merck KGaA Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Merck KGaA Nanobody Drug Product Portfolios and Specifications
Table 86. Merck KGaA Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Merck KGaA Main Business
Table 88. Merck KGaA Latest Developments
Table 89. Jerry Corning Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Jerry Corning Nanobody Drug Product Portfolios and Specifications
Table 91. Jerry Corning Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Jerry Corning Main Business
Table 93. Jerry Corning Latest Developments
Table 94. Shenzhen Pregene Biopharma Co Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolios and Specifications
Table 96. Shenzhen Pregene Biopharma Co Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Shenzhen Pregene Biopharma Co Main Business
Table 98. Shenzhen Pregene Biopharma Co Latest Developments
Table 99. Novamab Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Novamab Nanobody Drug Product Portfolios and Specifications
Table 101. Novamab Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Novamab Main Business
Table 103. Novamab Latest Developments
Table 104. PersonGen Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. PersonGen Nanobody Drug Product Portfolios and Specifications
Table 106. PersonGen Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. PersonGen Main Business
Table 108. PersonGen Latest Developments
Table 109. Nanjing Legend Biotechnology Co., Ltd. Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolios and Specifications
Table 111. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Nanjing Legend Biotechnology Co., Ltd. Main Business
Table 113. Nanjing Legend Biotechnology Co., Ltd. Latest Developments
Table 114. Taiwan Taisho Pharmaceutical Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolios and Specifications
Table 116. Taiwan Taisho Pharmaceutical Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Taiwan Taisho Pharmaceutical Main Business
Table 118. Taiwan Taisho Pharmaceutical Latest Developments
Table 119. Yiteng Pharmaceutical Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Yiteng Pharmaceutical Nanobody Drug Product Portfolios and Specifications
Table 121. Yiteng Pharmaceutical Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Yiteng Pharmaceutical Main Business
Table 123. Yiteng Pharmaceutical Latest Developments
Table 124. Beijing Shuoxing Biotechnology Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolios and Specifications
Table 126. Beijing Shuoxing Biotechnology Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Beijing Shuoxing Biotechnology Main Business
Table 128. Beijing Shuoxing Biotechnology Latest Developments
Table 1. Nanobody Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Nanobody Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monovalent Nanobodies
Table 4. Major Players of Multivalent Nanobodies
Table 5. Major Players of Fusion Nanobodies
Table 6. Major Players of Others
Table 7. Global Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 8. Global Nanobody Drug Sales Market Share by Type (2021-2026)
Table 9. Global Nanobody Drug Revenue by Type (2021-2026) & ($ million)
Table 10. Global Nanobody Drug Revenue Market Share by Type (2021-2026)
Table 11. Global Nanobody Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Nanobody Drug Sale by Application (2021-2026) & (K Units)
Table 13. Global Nanobody Drug Sale Market Share by Application (2021-2026)
Table 14. Global Nanobody Drug Revenue by Application (2021-2026) & ($ million)
Table 15. Global Nanobody Drug Revenue Market Share by Application (2021-2026)
Table 16. Global Nanobody Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Nanobody Drug Sales by Company (2021-2026) & (K Units)
Table 18. Global Nanobody Drug Sales Market Share by Company (2021-2026)
Table 19. Global Nanobody Drug Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Nanobody Drug Revenue Market Share by Company (2021-2026)
Table 21. Global Nanobody Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Nanobody Drug Producing Area Distribution and Sales Area
Table 23. Players Nanobody Drug Products Offered
Table 24. Nanobody Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Nanobody Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Nanobody Drug Sales Market Share Geographic Region (2021-2026)
Table 29. Global Nanobody Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Nanobody Drug Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Nanobody Drug Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Nanobody Drug Sales Market Share by Country/Region (2021-2026)
Table 33. Global Nanobody Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Nanobody Drug Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 36. Americas Nanobody Drug Sales Market Share by Country (2021-2026)
Table 37. Americas Nanobody Drug Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 39. Americas Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 40. APAC Nanobody Drug Sales by Region (2021-2026) & (K Units)
Table 41. APAC Nanobody Drug Sales Market Share by Region (2021-2026)
Table 42. APAC Nanobody Drug Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 44. APAC Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 45. Europe Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 46. Europe Nanobody Drug Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 48. Europe Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Nanobody Drug Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Nanobody Drug Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Nanobody Drug Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Nanobody Drug Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Nanobody Drug
Table 54. Key Market Challenges & Risks of Nanobody Drug
Table 55. Key Industry Trends of Nanobody Drug
Table 56. Nanobody Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Nanobody Drug Distributors List
Table 59. Nanobody Drug Customer List
Table 60. Global Nanobody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Nanobody Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Nanobody Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Nanobody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Nanobody Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Nanobody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Nanobody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Nanobody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Nanobody Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Nanobody Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Nanobody Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Nanobody Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Boehringer Ingelheim Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Boehringer Ingelheim Nanobody Drug Product Portfolios and Specifications
Table 76. Boehringer Ingelheim Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Boehringer Ingelheim Main Business
Table 78. Boehringer Ingelheim Latest Developments
Table 79. Sanofi Company(Ablynx) Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Sanofi Company(Ablynx) Nanobody Drug Product Portfolios and Specifications
Table 81. Sanofi Company(Ablynx) Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Sanofi Company(Ablynx) Main Business
Table 83. Sanofi Company(Ablynx) Latest Developments
Table 84. Merck KGaA Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Merck KGaA Nanobody Drug Product Portfolios and Specifications
Table 86. Merck KGaA Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Merck KGaA Main Business
Table 88. Merck KGaA Latest Developments
Table 89. Jerry Corning Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Jerry Corning Nanobody Drug Product Portfolios and Specifications
Table 91. Jerry Corning Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Jerry Corning Main Business
Table 93. Jerry Corning Latest Developments
Table 94. Shenzhen Pregene Biopharma Co Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolios and Specifications
Table 96. Shenzhen Pregene Biopharma Co Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Shenzhen Pregene Biopharma Co Main Business
Table 98. Shenzhen Pregene Biopharma Co Latest Developments
Table 99. Novamab Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Novamab Nanobody Drug Product Portfolios and Specifications
Table 101. Novamab Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Novamab Main Business
Table 103. Novamab Latest Developments
Table 104. PersonGen Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. PersonGen Nanobody Drug Product Portfolios and Specifications
Table 106. PersonGen Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. PersonGen Main Business
Table 108. PersonGen Latest Developments
Table 109. Nanjing Legend Biotechnology Co., Ltd. Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolios and Specifications
Table 111. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Nanjing Legend Biotechnology Co., Ltd. Main Business
Table 113. Nanjing Legend Biotechnology Co., Ltd. Latest Developments
Table 114. Taiwan Taisho Pharmaceutical Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolios and Specifications
Table 116. Taiwan Taisho Pharmaceutical Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Taiwan Taisho Pharmaceutical Main Business
Table 118. Taiwan Taisho Pharmaceutical Latest Developments
Table 119. Yiteng Pharmaceutical Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Yiteng Pharmaceutical Nanobody Drug Product Portfolios and Specifications
Table 121. Yiteng Pharmaceutical Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Yiteng Pharmaceutical Main Business
Table 123. Yiteng Pharmaceutical Latest Developments
Table 124. Beijing Shuoxing Biotechnology Basic Information, Nanobody Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolios and Specifications
Table 126. Beijing Shuoxing Biotechnology Nanobody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Beijing Shuoxing Biotechnology Main Business
Table 128. Beijing Shuoxing Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Nanobody Drug
Figure 2. Nanobody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nanobody Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Nanobody Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Nanobody Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Nanobody Drug Sales Market Share by Country/Region (2025)
Figure 10. Nanobody Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monovalent Nanobodies
Figure 12. Product Picture of Multivalent Nanobodies
Figure 13. Product Picture of Fusion Nanobodies
Figure 14. Product Picture of Others
Figure 15. Global Nanobody Drug Sales Market Share by Type in 2026
Figure 16. Global Nanobody Drug Revenue Market Share by Type (2021-2026)
Figure 17. Nanobody Drug Consumed in Tumor Treatment
Figure 18. Global Nanobody Drug Market: Tumor Treatment (2021-2026) & (K Units)
Figure 19. Nanobody Drug Consumed in Immune Disease Treatment
Figure 20. Global Nanobody Drug Market: Immune Disease Treatment (2021-2026) & (K Units)
Figure 21. Nanobody Drug Consumed in Inflammatory Disease Treatment
Figure 22. Global Nanobody Drug Market: Inflammatory Disease Treatment (2021-2026) & (K Units)
Figure 23. Nanobody Drug Consumed in Others
Figure 24. Global Nanobody Drug Market: Others (2021-2026) & (K Units)
Figure 25. Global Nanobody Drug Sale Market Share by Application (2025)
Figure 26. Global Nanobody Drug Revenue Market Share by Application in 2026
Figure 27. Nanobody Drug Sales by Company in 2026 (K Units)
Figure 28. Global Nanobody Drug Sales Market Share by Company in 2026
Figure 29. Nanobody Drug Revenue by Company in 2026 ($ millions)
Figure 30. Global Nanobody Drug Revenue Market Share by Company in 2026
Figure 31. Global Nanobody Drug Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Nanobody Drug Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Nanobody Drug Sales 2021-2026 (K Units)
Figure 34. Americas Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 35. APAC Nanobody Drug Sales 2021-2026 (K Units)
Figure 36. APAC Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 37. Europe Nanobody Drug Sales 2021-2026 (K Units)
Figure 38. Europe Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Nanobody Drug Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 41. Americas Nanobody Drug Sales Market Share by Country in 2026
Figure 42. Americas Nanobody Drug Revenue Market Share by Country (2021-2026)
Figure 43. Americas Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 44. Americas Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 45. United States Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Nanobody Drug Sales Market Share by Region in 2026
Figure 50. APAC Nanobody Drug Revenue Market Share by Region (2021-2026)
Figure 51. APAC Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 52. APAC Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 53. China Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. India Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Nanobody Drug Sales Market Share by Country in 2026
Figure 61. Europe Nanobody Drug Revenue Market Share by Country (2021-2026)
Figure 62. Europe Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 63. Europe Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 64. Germany Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. France Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Nanobody Drug Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 72. Egypt Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Nanobody Drug in 2026
Figure 78. Manufacturing Process Analysis of Nanobody Drug
Figure 79. Industry Chain Structure of Nanobody Drug
Figure 80. Channels of Distribution
Figure 81. Global Nanobody Drug Sales Market Forecast by Region (2027-2032)
Figure 82. Global Nanobody Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Nanobody Drug Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Nanobody Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Nanobody Drug Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Nanobody Drug Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Nanobody Drug
Figure 2. Nanobody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nanobody Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Nanobody Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Nanobody Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Nanobody Drug Sales Market Share by Country/Region (2025)
Figure 10. Nanobody Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monovalent Nanobodies
Figure 12. Product Picture of Multivalent Nanobodies
Figure 13. Product Picture of Fusion Nanobodies
Figure 14. Product Picture of Others
Figure 15. Global Nanobody Drug Sales Market Share by Type in 2026
Figure 16. Global Nanobody Drug Revenue Market Share by Type (2021-2026)
Figure 17. Nanobody Drug Consumed in Tumor Treatment
Figure 18. Global Nanobody Drug Market: Tumor Treatment (2021-2026) & (K Units)
Figure 19. Nanobody Drug Consumed in Immune Disease Treatment
Figure 20. Global Nanobody Drug Market: Immune Disease Treatment (2021-2026) & (K Units)
Figure 21. Nanobody Drug Consumed in Inflammatory Disease Treatment
Figure 22. Global Nanobody Drug Market: Inflammatory Disease Treatment (2021-2026) & (K Units)
Figure 23. Nanobody Drug Consumed in Others
Figure 24. Global Nanobody Drug Market: Others (2021-2026) & (K Units)
Figure 25. Global Nanobody Drug Sale Market Share by Application (2025)
Figure 26. Global Nanobody Drug Revenue Market Share by Application in 2026
Figure 27. Nanobody Drug Sales by Company in 2026 (K Units)
Figure 28. Global Nanobody Drug Sales Market Share by Company in 2026
Figure 29. Nanobody Drug Revenue by Company in 2026 ($ millions)
Figure 30. Global Nanobody Drug Revenue Market Share by Company in 2026
Figure 31. Global Nanobody Drug Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Nanobody Drug Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Nanobody Drug Sales 2021-2026 (K Units)
Figure 34. Americas Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 35. APAC Nanobody Drug Sales 2021-2026 (K Units)
Figure 36. APAC Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 37. Europe Nanobody Drug Sales 2021-2026 (K Units)
Figure 38. Europe Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Nanobody Drug Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Nanobody Drug Revenue 2021-2026 ($ millions)
Figure 41. Americas Nanobody Drug Sales Market Share by Country in 2026
Figure 42. Americas Nanobody Drug Revenue Market Share by Country (2021-2026)
Figure 43. Americas Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 44. Americas Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 45. United States Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Nanobody Drug Sales Market Share by Region in 2026
Figure 50. APAC Nanobody Drug Revenue Market Share by Region (2021-2026)
Figure 51. APAC Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 52. APAC Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 53. China Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. India Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Nanobody Drug Sales Market Share by Country in 2026
Figure 61. Europe Nanobody Drug Revenue Market Share by Country (2021-2026)
Figure 62. Europe Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 63. Europe Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 64. Germany Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. France Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Nanobody Drug Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Nanobody Drug Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Nanobody Drug Sales Market Share by Application (2021-2026)
Figure 72. Egypt Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Nanobody Drug Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Nanobody Drug in 2026
Figure 78. Manufacturing Process Analysis of Nanobody Drug
Figure 79. Industry Chain Structure of Nanobody Drug
Figure 80. Channels of Distribution
Figure 81. Global Nanobody Drug Sales Market Forecast by Region (2027-2032)
Figure 82. Global Nanobody Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Nanobody Drug Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Nanobody Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Nanobody Drug Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Nanobody Drug Revenue Market Share Forecast by Application (2027-2032)
